English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Pharma & Biotech BioTech
Oculis委任丁伟波先生为全球首席营运官兼中国区总经理
Jan 05, 2022 15:29 HKT
Oculis委任丁偉波先生為全球首席營運官兼中國區總經理
Jan 05, 2022 15:28 HKT
Oculis appoints Mr. Webb Ding as Global Chief Operating Officer and General Manager (China)
Jan 05, 2022 15:27 HKT
冠科美博(Apollomics)首席执行官余国良博士当选为百华协会 (BayHelix Group) 董事会主席
Jan 04, 2022 10:12 HKT
冠科美博(Apollomics)首席執行官余國良博士當選為百華協會 (BayHelix Group) 董事會主席
Jan 04, 2022 10:11 HKT
Apollomics Inc. Announces CEO Guo-Liang Yu, PhD Appointed as Chairman of the Board for the BayHelix Group
Jan 04, 2022 10:10 HKT
在中国和美国均拥有重要运营布局的首家临床阶段RNA疗法生物制药公司Sirnaomics Ltd.于香港联合交易所主板挂牌
Dec 30, 2021 15:57 HKT
在中國和美國均擁有重要運營佈局的首家臨床階段RNA療法生物製藥公司Sirnaomics Ltd.於香港聯合交易所主板掛牌
Dec 30, 2021 15:56 HKT
Sirnaomics Ltd., RNA Therapeutics Biopharmaceutical Company with Presence in China and US, Lists on Main Board of SEHK
Dec 30, 2021 15:55 HKT
独立股评人陈永陆︰圣诺医药可认购
Dec 21, 2021 08:56 HKT
獨立股評人陳永陸︰聖諾醫藥可認購
Dec 21, 2021 08:55 HKT
Sirnaomics Ltd.宣布于港交所主板上市计划
Dec 19, 2021 20:50 HKT
Sirnaomics Ltd.宣佈於港交所主板上市計劃
Dec 19, 2021 20:49 HKT
Sirnaomics Ltd. Announces Proposed Listing on the Main Board of SEHK
Dec 19, 2021 20:48 HKT
Pharmaron recognized with 2 Awards at China Securities Golden Bauhinia Awards Ceremony
Dec 17, 2021 17:45 HKT
Acumen Diagnostics granted Ministry of Health COVID-19 offsite PCR testing license, up to 100 sites island-wide
Dec 16, 2021 11:00 HKT
호흡기 관련 의학 저널 란셋, 렌질루맙 3상 실험의 긍정적 결과에 대한 동료 평가 기반 논문 및 독립 전문가 논평 발간
Dec 13, 2021 23:00 HKT
HMI Group Expands Singapore Presence, Doubles Down on Value-based Care Offering
Dec 10, 2021 13:00 HKT
Biolidics to Commence Commercial Production of its ClearEpi SARS-COV-2 Neutralising Antibody Rapid Test Kit
Dec 09, 2021 08:32 HKT
Avantor Provides Critical Personal Protection Supplies to Vulnerable Populations through NGOs
Dec 06, 2021 10:00 HKT
<< Previous  Next >>
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: